ScholarIQanswers from OpenAlex
Providence Portland Medical Center
InstitutionResearch output, impact & collaborations
Providence Portland Medical Center is a institution indexed in ScholarIQ from OpenAlex.
What is known about Providence Portland Medical Center?
ScholarIQrecord summary
Providence Portland Medical Center is a research organisation in Portland, US. OpenAlex records 3,070 works and 347,062 citations for it. 715 researchers list it as their most recent affiliation.
How many works does Providence Portland Medical Center have?
ScholarIQindexed works
Providence Portland Medical Center has 3,070 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Providence Portland Medical Center have?
ScholarIQcitation count
Providence Portland Medical Center has 347,062 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Providence Portland Medical Center?
ScholarIQresearcher count
Providence Portland Medical Center has 715 researchers in the ScholarIQ index.
What is the average h-index at Providence Portland Medical Center?
ScholarIQavg h-index
Providence Portland Medical Center has an average h-index of 51.7 in OpenAlex.
What is the ROR of Providence Portland Medical Center?
ScholarIQror
The ROR for Providence Portland Medical Center is on the source record.
What is the OpenAlex record for Providence Portland Medical Center?
ScholarIQopenalex
The OpenAlex for Providence Portland Medical Center is on the source record.
What is the Wikidata of Providence Portland Medical Center?
ScholarIQwikidata
The Wikidata for Providence Portland Medical Center is on the source record.
Who are the most-cited researchers behind Providence Portland Medical Center?
ScholarIQtop researchers by citations
What are the most-cited papers on Providence Portland Medical Center?
ScholarIQmost cited works
Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children
Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar, Steven G. DuBois, Ulrik Lassen, George D. Demetri, Michael J. Nathenson, Robert C. Doebele, Anna F. Farago, Alberto S. Pappo, Brian Turpin, Afshin Dowlati, Marcia S. Brose, Leo Mascarenhas, Noah Federman, Jordan Berlin, Wafik S. El‐Deiry, Christina S. Baik, John F. Deeken, Valentina Boni, Ramamoorthy Nagasubramanian, Matthew H. Taylor, Erin R. Rudzinski, Funda Meric‐Bernstam, Davendra Sohal, C. Patrick, Luis E. Raez, Jaclyn F. Hechtman, Ryma Benayed, Marc Ladanyi, Brian B. Tuch, Kevin Ebata, Scott Cruickshank, Nora Ku, Michael C. Cox, Douglas S. Hawkins, David S. Hong, David M. Hyman
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger, Makoto Tahara, Lori J. Wirth, Bruce Robinson, Marcia S. Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H. Shah, Ana O. Hoff, Andrew G. Gianoukakis, Naomi Kiyota, Matthew H. Taylor, Sung‐Bae Kim, Monika K. Krzyzanowska, Corina E. Dutcus, Begoña de las Heras, Junming Zhu, Steven I. Sherman
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan, Jessica C. Hassel, Piotr Rutkowski, Jean‐François Baurain, Marcus O. Butler, Max Schlaak, Ryan J. Sullivan, Sebastian Ochsenreither, Reinhard Dummer, John M. Kirkwood, Anthony M. Joshua, Joseph J. Sacco, Alexander N. Shoushtari, Marlana Orloff, Josep M. Piulats, Mohammed Milhem, April K.S. Salama, Brendan D. Curti, Lev Demidov, Lauris Gastaud, Cornelia Mauch, Melinda Yushak, Richard D. Carvajal, Omid Hamid, Shaad E. Abdullah, Chris Holland, Howard Goodall, Sophie Piperno‐Neumann
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Douglas J. Schwartzentruber, David H. Lawson, Jon Richards, Robert M. Conry, Donald M. Miller, Jonathan Treisman, Fawaz Gailani, Lee B. Riley, Kevin C. Conlon, Barbara A. Pockaj, Kari Kendra, Richard L. White, René González, Timothy M. Kuzel, Brendan D. Curti, Phillip D. Leming, Eric D. Whitman, Jai Balkissoon, Douglas S. Reintgen, Howard L. Kaufman, Francesco M. Marincola, Maria J. Merino, Steven A. Rosenberg, Peter L. Choyke, Don Vena, Patrick Hwu
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
Lori J. Wirth, Eric J. Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen H. Lorch, Francis P. Worden, Marcia S. Brose, Jyoti D. Patel, Sophie Leboulleux, Yann Godbert, Fabrice Barlési, John C. Morris, Taofeek K. Owonikoko, Daniel S.W. Tan, Oliver Gautschi, Jared Weiss, Christelle de la Fouchardière, Mark E. Burkard, Janessa Laskin, Matthew H. Taylor, Matthias Kroiß, Jacques Médioni, Jonathan W. Goldman, Todd M. Bauer, Benjamin Levy, Viola W. Zhu, Nehal J. Lakhani, Víctor Moreno, Kevin Ebata, Michele Nguyen, Dana Heirich, Edward Y. Zhu, Xin Huang, Luxi Yang, Jennifer Kherani, S. Michael Rothenberg, Alexander Drilon, Vivek Subbiah, Manisha H. Shah, Maria E. Cabanillas
Who collaborates most closely around Providence Portland Medical Center?
ScholarIQco-authorship network
United States
100%
MOST FREQUENT PARTNER INSTITUTIONS
How much of the research on Providence Portland Medical Center is open access?
ScholarIQopen access share
82%OPEN ACCESS